Clinical trial • Not applicable • Endocrinology|Other

INDOCYANINE GREEN for Hypothyroidism|Hypoparathyroidism

Not applicable trial of INDOCYANINE GREEN for Hypothyroidism|Hypoparathyroidism.

Overview

Trial Therapeutic Area
Endocrinology|Other
Trial Disease
Hypothyroidism|Hypoparathyroidism
Trial Stage
Not applicable
Drug Modality
Diagnostic agent

Key dates

Initial CTIS Submission Date
25-10-2023
First CTIS Authorization Date
24-01-2024

Trial design

Randomised, two arms: arm with intraoperative indocyanine green (indocyanine green) arteriography (intravenous administration; product maximum total dose reported as 5 mg/kg) versus arm without icg (standard surgery without icg arteriography).-controlled Not applicable trial across 3 sites in Spain.

Randomised
Yes
Comparator
Two arms: Arm with intraoperative indocyanine green (INDOCYANINE GREEN) arteriography (intravenous administration; product maximum total dose reported as 5 mg/kg) versus arm without ICG (standard surgery without ICG arteriography).
Target Sample Size
394
Trial Duration For Participant
365

Eligibility

Recruits 394 The protocol states: "The patient or legal guardian can understand the study and agrees to participate by signing the written informed consent." Vulnerable population selection is marked as not selected (isVulnerablePopulationSelected=false). Consent is required from the patient or legal guardian as specified. No assent process or age‑specific consent documents or additional vulnerable-population procedures are described..

Vulnerable Population
The protocol states: "The patient or legal guardian can understand the study and agrees to participate by signing the written informed consent." Vulnerable population selection is marked as not selected (isVulnerablePopulationSelected=false). Consent is required from the patient or legal guardian as specified. No assent process or age‑specific consent documents or additional vulnerable-population procedures are described.

Inclusion criteria

  • {"criterion_text":"- Patients ≥18 years of age with a surgical indication for total thyroidectomy with or without central cervical lymph node dissection due to thyroid disease."}
  • {"criterion_text":"- The patient or legal guardian can understand the study and agrees to participate by signing the written informed consent."}

Exclusion criteria

  • {"criterion_text":"- Previous surgical intervention on the thyroid or parathyroid gland."}
  • {"criterion_text":"- Evidence of associated hyperparathyroidism requiring a parathyroidectomy in the same surgical procedure."}
  • {"criterion_text":"- Patients with known contraindications to ICG."}

Endpoints

Primary endpoints

  • {"endpoint_text":"- Number (percentage) of PG preserved with intraoperative ICG arteriography and the number (percentage) of preserved PG without it.","definition_or_measurement_approach":"Measured as the number and percentage of parathyroid glands (PG) preserved in each arm: with intraoperative ICG arteriography versus without ICG arteriography."}

Secondary endpoints

  • {"endpoint_text":"- Preoperative calcium, total protein, vitamin D, and PTH serum levels","definition_or_measurement_approach":"Measured as laboratory serum values of total calcium, total protein, vitamin D and PTH prior to surgery."}
  • {"endpoint_text":"- Number of well perfused GP in situ","definition_or_measurement_approach":"Count of parathyroid glands assessed intraoperatively as well perfused (in situ)."}
  • {"endpoint_text":"- GP score according to the black and white system","definition_or_measurement_approach":"Scoring of parathyroid gland perfusion using the black and white system as defined in the protocol."}
  • {"endpoint_text":"- Surgery duration","definition_or_measurement_approach":"Measured as operative time (duration of surgery)."}
  • {"endpoint_text":"- Intraoperative PTH serum level","definition_or_measurement_approach":"Measurement of parathyroid hormone (PTH) levels during the operation."}
  • {"endpoint_text":"- Serum PTH, calcium, and total protein levels at 24h after surgery","definition_or_measurement_approach":"Laboratory measurement of serum PTH, calcium and total protein at 24 hours post-operation."}
  • {"endpoint_text":"- Serum PTH levels 1, 3, 6 and 12 months after surgery","definition_or_measurement_approach":"Laboratory measurement of serum PTH at 1, 3, 6 and 12 months post-operation."}
  • {"endpoint_text":"- Presence or absence of hypoparathyroidism during the one-year follow-up. Hypoparathyroidism is defined as undetectable or inappropriately low serum PTH levels in the context of hypocalcemia.","definition_or_measurement_approach":"Determined during one-year follow-up by serum PTH and calcium: hypoparathyroidism defined as undetectable or inappropriately low PTH in the context of hypocalcemia."}

Recruitment

Planned Sample Size
394
Recruitment Window Months
36
Consent Approach
Written informed consent is required. The protocol states: "The patient or legal guardian can understand the study and agrees to participate by signing the written informed consent." No details on age‑specific documents, assent, or languages of consent forms are provided in the available record.

Geography

Total Number Of Sites
3
Total Number Of Participants
394

Spain

Earliest CTIS Part Ii Submission Date
23-12-2023
Latest Decision Or Authorization Date
24-01-2024
Processing Time Days
32
Number Of Sites
3
Number Of Participants
394

Sites

Site Name
Hospital Clinic De Barcelona
Department Name
General and Digestive Surgery
Contact Person Name
Oscar Vidal
Contact Person Email
ovidal@clinic.cat
Site Name
Hospital Universitario Basurto
Department Name
General and Digestive Surgery
Contact Person Name
Amaya Exposito
Site Name
Bellvitge University Hospital
Department Name
General and Digestive Surgery
Contact Person Name
Pablo Moreno
Contact Person Email
25108pml@gmail.com

Sponsor

Primary sponsor

Full Name
Bellvitge University Hospital
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
Spain

Investigational products

Investigational Product Name
INDOCYANINE GREEN
Active Substance
INDOCYANINE GREEN
Modality
Diagnostic agent
Routes Of Administration
Intravenous administration
Route
Intravenous
Authorisation Status
Authorised for other indications (used in routine clinical practice for imaging)
Maximum Dose
5 mg/kg

Related trials

Other published trials that may interest you.